Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 17Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Lambert-Eaton Myasthenic Syndrome 1Immunoblastic Lymphadenopathy 1Hormone-Resistant Prostate Cancer 1Enteropathy-Associated T-Cell Lymphoma 1Down Syndrome 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

prednylidene 1deltacortene 1apalutamide 1Prednisone 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stage II Prostate Adenocarcinoma × prednylidene × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡